Breakthrough Cholesterol Drug Gets Ambivalent Endorsement

Forbes: Regeneron’s high-powered cholesterol shot, Praluent, just got recommended 13 to 3 for approval by a panel convened to advise the Food and Drug Administration. But there were so many caveats that insurers are probably doing a happy dance about their likely ability to restrict its use. Amgen AMGN -1.07%, whose rival drug Repatha goes before the same panel tomorrow, has reason to be nervous.

Read article

Share